Bayer’s BAY2927088 to face competition, says analyst

German pharma major Bayer’s (BAYN: DE) BAY2927088 recently received Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China.

Following approval, BAY2927088 is expected to face intense competition in the epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) but limited competition in the human epidermal growth factor receptor 2 (HER2)-exon 20 mutant NSCLC market in China, says pharma analytics company GlobalData.

BAY2927088 is an oral, tyrosine kinase inhibitor (TKI) that inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations, as well as EGFR, with high selectivity for mutant vs. wild-type EGFR in adult patients with unresectable or metastatic NSCLC and who have received prior systemic therapy.